What is Vasopressin?
Arginine vasopressin is a nine-residue hormone involved in water balance and vascular tone. VASST compared vasopressin with norepinephrine in septic shock.
Biological role or research focus
Fluid balance and vasopressor research.
An apparent subgroup difference in less severe shock does not establish overall mortality superiority. Critical-care treatment context limits application to other populations.
Role reference: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
Names you may encounter
Arginine vasopressin · AVP
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Endogenous nonapeptide hormone
- Research focus
- Fluid balance and vasopressor research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Source: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
Quick answers
- Is Vasopressin FDA approved?
- Yes. Vasostrict (NDA 204485, approved 2014) and other vasopressin injections to raise blood pressure in adults with vasodilatory shock. Source ↗
- Is Vasopressin safe?
- Vasopressin injection is an ICU drug that raises blood pressure in shock; reported harms include reduced heart output, loss of blood flow to the gut, limbs or heart, low sodium and diabetes insipidus after stopping. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Vasopressin banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S5 Diuretics and masking agents). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| VASST (2008) | Human randomized trial | 778 patients with septic shock who were already receiving vasopressors. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2008
VASST
Did vasopressin reduce overall mortality versus norepinephrine?
- Population / model
- 778 patients with septic shock who were already receiving vasopressors.
- Study design
- Randomized blinded comparison of vasopressin and norepinephrine, with 28- and 90-day mortality outcomes.
- Main finding
- Mortality at 28 days was 35.4% versus 39.3% (P=0.26). At 90 days it was 43.9% versus 49.6% (P=0.11). Neither overall comparison was statistically significant.
- Limits & context
- An apparent subgroup difference in less severe shock does not establish overall mortality superiority. Critical-care treatment context limits application to other populations.
Source: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
33 registered studies name Vasopressin as an intervention among the 100 most recently updated of 529 search results; 19 are recruiting or under way, 3 have not started recruiting yet, 10 completed and 1 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial NCT05139849 · Tiohundra AB | Recruiting | Phase 3 | 2026-10-12 | 784 |
| CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial NCT05958342 · Jason Sperry | Recruiting | Phase 2 | 2024-06-30 | 1050 |
| Vasopressin and Pain Perception in the Brain NCT03446456 · University of Maryland, Baltimore | Recruiting | Phase 1 / Phase 2 | 2018-09-17 | 56 |
| Hemodynamic Effect of Norepinephrine Versus Vasopressin on the Pulmonary Circulation in Cardiac Surgery Patients: NCT04501861 · The Cleveland Clinic | Completed | Phase 3 | 2020-11-05 | 153 |
| Systematic Adjunction of Vasopressine in Septic Shock NCT07052084 · Assistance Publique Hopitaux De Marseille | Recruiting | Phase 3 | 2026-03-24 | 120 |
| Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency NCT04789148 · Elizabeth Austen Lawson | Recruiting | Phase 1 | 2025-09-10 | 40 |
| Norepinephrine Equivalent Dose of Vasopressin, Phenylephrine and Epinephrine in Septic Shock NCT06499467 · Sanjay Gandhi Postgraduate Institute of Medical Sciences | Completed | 2024-07-12 | 120 | |
| Intracervical Vasopressin NCT07102615 · Prisma Health-Upstate | Recruiting | Phase 4 | 2025-10-30 | 50 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 33 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Vasopressin. ↗
· 2006 · Review
Optimizing Vasopressin Use and Initiation Timing in Septic Shock: A Narrative Review. ↗
Chest · 2023 Nov · Journal Article, Review, Research Support, N.I.H., Extramural
Read available full text ↗
Vasopressin. ↗
Seminars in respiratory and critical care medicine · 2004 Dec · Journal Article
The Biology of Vasopressin. ↗
Biomedicines · 2021 Jan 18 · Journal Article, Review
Read available full text ↗
Risks & interactions
Vasopressin injection is an ICU drug that raises blood pressure in shock; reported harms include reduced heart output, loss of blood flow to the gut, limbs or heart, low sodium and diabetes insipidus after stopping.
Safety is established by FDA labeling for use in vasodilatory shock under hospital monitoring. The side effects listed come from published reports, so how often they occur is unknown. There are no data in pregnancy.
Take extra care with: Heart or blood pressure problemsBlood thinners or bleeding problems
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- Allergy to vasopressin or chlorobutanol (a preservative in some vials)
Interactions
- Catecholamines such as norepinephrine: added effects on blood pressure
- Indomethacin: may prolong vasopressin's effects on the heart and blood vessels
- Ganglionic blocking agents: stronger rise in blood pressure
- Drugs linked to SIADH, such as SSRIs and tricyclic antidepressants: stronger blood-pressure and water-retaining effects
- Drugs linked to diabetes insipidus, such as lithium and demeclocycline: weaker effect
Serious risks
- Reduced heart output (cardiac index)
- Reversible diabetes insipidus after stopping
- Ischemia of the gut, fingers and toes, or heart muscle
- Low sodium
- Abnormal heart rhythms and right heart failure
- Bleeding and low platelets
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Vasopressin injection prescribing information ↗
What the featured evidence can tell us
Vasopressor effects require close clinical monitoring. The selected trial cannot support unsupervised use or establish safety in healthy people.
Source: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
Identity, route, and evidence limits
An apparent subgroup difference in less severe shock does not establish overall mortality superiority. Critical-care treatment context limits application to other populations.
Source: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
Official product context · checked October 4, 2026
The label describes reduced cardiac output, rhythm disturbances, low sodium, and ischemia. Increasing blood pressure is not, by itself, proof of a survival benefit.
Source: DailyMed · Vasostrict prescribing information ↗
Regulatory status
- U.S. FDA approval
- Approved
Vasostrict (NDA 204485, approved 2014) and other vasopressin injections to raise blood pressure in adults with vasodilatory shock. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S5 Diuretics and masking agents
Not named. S5 names desmopressin and covers substances with similar structure or effect, with an exception only for dental felypressin, so vasopressin is likely covered. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Medicine status & clinical context
The U.S. Vasostrict label concerns adults with vasodilatory shock whose low blood pressure persists despite fluids and catecholamines. This hospital vasopressor use is distinct from the natural hormone’s role in water balance.
The featured study concerns supervised vasopressor treatment in septic shock. It is not research on general hydration, longevity, or consumer supplementation.
Source: DailyMed · Vasostrict prescribing information ↗
Source: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
How Vasopressin works
Vasopressin pathways connect water retention with vascular effects. A physiologic receptor effect does not automatically translate into a survival advantage in critical illness.
Source: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
Molecular structure
Questions worth asking
- Was vasopressin proven to reduce overall mortality?
- What population, comparator, and route were actually studied?
- An apparent subgroup difference in less severe shock does not establish overall mortality superiority. Critical-care treatment context limits application to other populations.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Was vasopressin proven to reduce overall mortality?
No. The overall mortality comparisons in VASST were not statistically significant. Subgroup results should not replace the primary overall finding.
Source: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Source: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
Does the official medicine reference cover every use discussed online?
No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
